학술논문

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
Document Type
Article
Source
In The Lancet Gastroenterology & Hepatology August 2021 6(8):649-658
Subject
Primary Research
Articles
Language
ISSN
2468-1253